Literature DB >> 8674284

Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness.

C Holst-Hansen1, B Johannessen, G Høyer-Hansen, J Rømer, V Ellis, N Brünner.   

Abstract

In order to invade and spread cancer cells must degrade extracellular matrix proteins. This degradation is catalysed by the concerted action of several enzymes, including the serine protease plasmin. Several experimental studies have shown that inhibition of plasmin formation reduces cancer cell invasion and metastasis, indicating a critical role of this proteolytic pathway in these processes. In order to further study the role of plasmin in cancer progression, we have characterized urokinase-type plasminogen activator (uPA) mediated plasmin formation in three human breast cancer cell lines. Using monoclonal antibodies against uPA and its receptor uPAR, we have investigated the contribution of uPA and uPAR to invasive capacity in an in vitro invasion assay. MDA-MB-231 BAG cells were found to express high protein levels of uPA, uPAR and PAI-1. MDA-MB 435 BAG cells produced low amounts of uPA, PAI-1 and moderate amounts of uPAR, whereas MCF-7 BAG cells showed low levels of uPA, uPAR and PAI-1 protein. In a plasmin generation assay MDA-MB-231 BAG cells were highly active in mediating plasmin formation, which could be abolished by adding either an anticatalytic monoclonal antibody to uPA (clone 5) or an anti-uPAR monoclonal antibody (clone R3), which blocks binding of uPA to uPAR. The two other cell lines lacked the capacity to mediate plasmin formation. In the Matrigel invasion assay the cells showed activity in this order: MCF-7 BAG < MDA-MB-435 BAG < MDA-MB-231 BAG. Testing MDA-MB-231 BAG cells in the Matrigel invasion assay revealed that invasion could be inhibited in a dose-dependent manner either by the clone 5 uPA antibody or by the clone R3 uPAR antibody, suggesting that the cell surface uPA system is actively involved in this invasive process. It is concluded that these three cell lines constitute a valuable model system for in vitro studies of the role of cell surface uPA in cancer cell invasion and has application in the search for novel compounds which inhibit mechanisms involved in uPA-mediated plasmin generation on cancer cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8674284     DOI: 10.1007/bf00053903

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  64 in total

1.  Internalization of the urokinase-plasminogen activator inhibitor type-1 complex is mediated by the urokinase receptor.

Authors:  D Olson; J Pöllänen; G Høyer-Hansen; E Rønne; K Sakaguchi; T C Wun; E Appella; K Danø; F Blasi
Journal:  J Biol Chem       Date:  1992-05-05       Impact factor: 5.157

2.  Role of the urokinase receptor in facilitating extracellular matrix invasion by cultured colon cancer.

Authors:  W Hollas; F Blasi; D Boyd
Journal:  Cancer Res       Date:  1991-07-15       Impact factor: 12.701

3.  Enzyme-linked immunosorbent assay for human urokinase-type plasminogen activator and its proenzyme using a combination of monoclonal and polyclonal antibodies.

Authors:  L S Nielsen; J Grøndahl-Hansen; P A Andreasen; L Skriver; J Zeuthen; K Danø
Journal:  J Immunoassay       Date:  1986

4.  Plasminogen activator inhibitor from human fibrosarcoma cells binds urokinase-type plasminogen activator, but not its proenzyme.

Authors:  P A Andreasen; L S Nielsen; P Kristensen; J Grøndahl-Hansen; L Skriver; K Danø
Journal:  J Biol Chem       Date:  1986-06-15       Impact factor: 5.157

5.  lacZ transduced human breast cancer xenografts as an in vivo model for the study of invasion and metastasis.

Authors:  N Brünner; E W Thompson; M Spang-Thomsen; J Rygaard; K Danø; J A Zwiebel
Journal:  Eur J Cancer       Date:  1992       Impact factor: 9.162

6.  Antibodies to plasminogen activator inhibit human tumor metastasis.

Authors:  L Ossowski; E Reich
Journal:  Cell       Date:  1983-12       Impact factor: 41.582

7.  A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer.

Authors:  N Pedersen; M Schmitt; E Rønne; M I Nicoletti; G Høyer-Hansen; M Conese; R Giavazzi; K Dano; W Kuhn; F Jänicke
Journal:  J Clin Invest       Date:  1993-11       Impact factor: 14.808

8.  Prevention of metastasis by inhibition of the urokinase receptor.

Authors:  C W Crowley; R L Cohen; B K Lucas; G Liu; M A Shuman; A D Levinson
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-01       Impact factor: 11.205

9.  Effects of linoleic acid on the growth and metastasis of two human breast cancer cell lines in nude mice and the invasive capacity of these cell lines in vitro.

Authors:  D P Rose; J M Connolly; X H Liu
Journal:  Cancer Res       Date:  1994-12-15       Impact factor: 12.701

10.  Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1.

Authors:  M V Cubellis; T C Wun; F Blasi
Journal:  EMBO J       Date:  1990-04       Impact factor: 11.598

View more
  41 in total

1.  Antagonistic anti-urokinase plasminogen activator receptor (uPAR) antibodies significantly inhibit uPAR-mediated cellular signaling and migration.

Authors:  Sai Duriseti; David H Goetz; Daniel R Hostetter; Aaron M LeBeau; Ying Wei; Charles S Craik
Journal:  J Biol Chem       Date:  2010-05-25       Impact factor: 5.157

2.  LCC15-MB cells are MDA-MB-435: a review of misidentified breast and prostate cell lines.

Authors:  Erik W Thompson; Mark Waltham; Susan J Ramus; Anne-Marie Hutchins; Jane E Armes; Ian G Campbell; Elizabeth D Williams; Phillip R Thompson; James M Rae; Michael D Johnson; Robert Clarke
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

3.  High glucose and insulin enhance uPA expression, ROS formation and invasiveness in breast cancer-derived cells.

Authors:  Luis Antonio Flores-López; María Guadalupe Martínez-Hernández; Rubí Viedma-Rodríguez; Margarita Díaz-Flores; Luis Arturo Baiza-Gutman
Journal:  Cell Oncol (Dordr)       Date:  2016-04-22       Impact factor: 6.730

4.  Tranexamic acid is an active site inhibitor of urokinase plasminogen activator.

Authors:  Guojie Wu; Blake A Mazzitelli; Adam J Quek; Matthew J Veldman; Paul J Conroy; Tom T Caradoc-Davies; Lisa M Ooms; Kellie L Tuck; Jonathan G Schoenecker; James C Whisstock; Ruby H P Law
Journal:  Blood Adv       Date:  2019-03-12

5.  RNAi-mediated downregulation of urokinase plasminogen activator and its receptor in human meningioma cells inhibits tumor invasion and growth.

Authors:  Shakuntala Kondraganti; Christopher S Gondi; Ian McCutcheon; Dzung H Dinh; Meena Gujrati; Jasti S Rao; William C Olivero
Journal:  Int J Oncol       Date:  2006-06       Impact factor: 5.650

6.  Downregulation of uPA, uPAR and MMP-9 using small, interfering, hairpin RNA (siRNA) inhibits glioma cell invasion, angiogenesis and tumor growth.

Authors:  Christopher S Gondi; Sajani S Lakka; Dzung H Dinh; William C Olivero; Meena Gujrati; Jasti S Rao
Journal:  Neuron Glia Biol       Date:  2004-05

7.  Involvement of hypoxia-inducing factor-1alpha-dependent plasminogen activator inhibitor-1 up-regulation in Cyr61/CCN1-induced gastric cancer cell invasion.

Authors:  Ming-Tsan Lin; I-Hsin Kuo; Cheng-Chi Chang; Chia-Yu Chu; Hsing-Yu Chen; Been-Ren Lin; Munisamy Sureshbabu; Hou-Jung Shih; Min-Liang Kuo
Journal:  J Biol Chem       Date:  2008-04-01       Impact factor: 5.157

8.  Augmented expression of urokinase plasminogen activator and extracellular matrix proteins associates with multiple myeloma progression.

Authors:  Rehan Khan; Nidhi Gupta; Raman Kumar; Manoj Sharma; Lalit Kumar; Alpana Sharma
Journal:  Clin Exp Metastasis       Date:  2014-05-08       Impact factor: 5.150

9.  Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery.

Authors:  Jessica Kao; Keyan Salari; Melanie Bocanegra; Yoon-La Choi; Luc Girard; Jeet Gandhi; Kevin A Kwei; Tina Hernandez-Boussard; Pei Wang; Adi F Gazdar; John D Minna; Jonathan R Pollack
Journal:  PLoS One       Date:  2009-07-03       Impact factor: 3.240

10.  Obesity and breast cancer: the roles of peroxisome proliferator-activated receptor-γ and plasminogen activator inhibitor-1.

Authors:  Jennifer C Carter; Frank C Church
Journal:  PPAR Res       Date:  2009-08-06       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.